Evidence map›Paper›PMID 42482749›Full record

ArticleFrontiers in oncology2026

Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report.

Chelsey M Williams, Susanne M Arnold, John L Villano, Erika N Amarilla Alonso, Christine F Brainson, Paul O Schwarzenberger, Sahista Vahora, Ayman Qasrawi, Reinhold Munker, B Mark Evers and 1 more

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05680922 (A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05680922 phase1active not recruitingnot on this map

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

TypeinterventionalSponsorLegend Biotech USA IncRan2023 to 2027Enrolled41ConditionsSmall Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the LungArmsLB2102
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chelsey M WilliamsDepartment of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, KY, United States.
Susanne M ArnoldDepartment of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, KY, United States.
John L VillanoDepartment of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, KY, United States.
Erika N Amarilla AlonsoUniversity of Kentucky College of Medicine, Lexington, KY, United States.
Christine F BrainsonDepartment of Toxicology and Cancer Biology, University of Kentucky Markey Cancer Center, Lexington, KY, United States.
Paul O SchwarzenbergerLegend Biotech USA Inc., Somerset, NJ, United States.
Sahista VahoraLegend Biotech USA Inc., Somerset, NJ, United States.
Ayman QasrawiDepartment of Medicine, Division of Hematology and Cellular Therapy, University of Kentucky Markey Cancer Center, Lexington, KY, United States.
Reinhold MunkerDepartment of Medicine, Division of Hematology and Cellular Therapy, University of Kentucky Markey Cancer Center, Lexington, KY, United States.
B Mark EversDepartment of Surgery, Markey Cancer Center, University of Kentucky Markey Cancer Center, Lexington, KY, United States.
Zhonglin HaoDepartment of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, KY, United States.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
Targeting Lung Fibrosis Using Epigenetic TherapyR01HL170193 · NHLBI · UNIVERSITY OF KENTUCKY · PI Christine Fillmore Brainson · 2024 to 2026
$2.1M
NCI NIH HHS P30 CA177558NHLBI NIH HHS R01 HL170193
6 · The paper itself

Abstract

Novel CAR-T therapies targeting delta-like ligand 3 (DLL-3) are promising treatment strategies for individuals with extensive-stage SCLC (ES-SCLC). We report a case of a patient with ES-SCLC who received investigational therapy LB2102 off-label after becoming ineligible for a clinical trial. We described her positive, long-term response to treatment. This case highlights efficacious use of this investigational drug in a real-world setting prior to release of final reported data from phase 1 trial NCT05680922.

Indexed as

CAR-Tcase reportDLL3ES-SCLCLB2102

Identifiers

PMID42482749
PMCPMC13384869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.